While, HSP90 is up-regulated in many diseases including cancer, treatment with HSP90 inhibitors evoked dissociation of HSP90 from phosphorylated Akt1 and subsequent degradation, highlighting a new potential therapeutic target for the treatment of cancer with up-regulated Akt activity [92,101]. Here, AKT1 is linked to cancer.